Characterization of individuals with chronic pain: phenotyping approaches used in MAPP by David A Williams
ORAL PRESENTATION Open Access
Characterization of individuals with chronic pain:
phenotyping approaches used in MAPP
David A Williams
From Seventh Scientific Meeting of The TMJ Association, Genetic, Epigenetic, and Mechanistic Studies of
Temporomandibular Disorders and Overlapping Pain Conditions
Bethesda, MD, USA. 7-9 September 2014
Pain is a complex perception affecting one’s state of con-
sciousness, functional status, and quality of life. Clinically,
pain intensity is often the only facet of pain that is
assessed; but two large research networks (i.e., the Orofa-
cial Pain: Prospective Evaluation and Risk Assessment
(OPPERA) [1] and the Multi-Disciplinary Approach to the
Study of Chronic Pelvic Pain (MAPP) [2]) have character-
ized pain in accordance with broader pain concepts.
MAPP was designed to characterize individuals with uro-
logic chronic pelvic pain syndromes (UCPPS) which con-
sisted of diagnoses such as interstitial cystitis, bladder pain
syndrome, chronic prostatitis, and chronic pelvic pain syn-
drome. Characterization of the sample of n=1039 indivi-
duals occurred at multiple sites and at multiple levels of
analysis including: biomarkers, self-report questionnaires,
quantitative sensory testing (QST), functional neurobiolo-
gical studies, and structured and resting state neuroima-
ging studies. A comprehensive assessment occurred at
baseline followed longitudinally by biweekly or bimonthly
internet questionnaires and more extensive in-clinic visits
at 24 and 48 weeks following baseline [3]. The self-report
methods covered both urologic-specific and non-urologi-
cal domains relevant to chronic pain which are consistent
with the bio-psycho-social model of pain. Urological
domains included urological diagnostics, symptoms and
impact, sexual functioning, self-esteem, and social rela-
tionships. Non-urological-specific self-assessment included
clinical pain, functional status, mood, co-morbid condi-
tions, personality, attitudes/ beliefs, and early life trauma.
Biological specimens linked to clinical data included cheek
swabs and plasma, as well as urine for exploration of infec-
tious etiology. Also linked to the clinical data was quanti-
tative sensory testing (QST) which helped to characterize
individuals with respect to pain threshold, and
neuroimaging studies providing structural, functional and
network connectivity data corresponding to central pain
processing and modulation. Ultimately, the goal of such
extensive phenotyping will be to identify subgroups of
individuals with UCPPS who have distinct underlying
pathophysiology to which more optimal treatment
approaches can be aligned thus offering the potential for
improved disease management and improved patient care.
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